Orlando Health Cancer Institute

Clinical research site in Orlando, Florida · 1414 KUHL AVE, MP 710, ORLANDO, FL 32806-2008 · (321) 841-6947 · Website

Part of Orlando Health Cancer Institute

As of July 2026, 36 paid clinical trials are recruiting at Orlando Health Cancer Institute in Orlando, Florida. Active studies at this site cover conditions such as Carcinoma, Non-Small-Cell Lung, Metastatic Melanoma and Metastatic Renal Cell Carcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Orlando Health Cancer Institute (36)

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

for Advanced Non-Small Cell Lung Cancer

186 locations incl. Bullhead City

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222566·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

for Carcinoma, Renal Cell

109 locations incl. Phoenix

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227415·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

for Advanced/Metastatic Non-Small Cell Lung Cancer

27 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227298·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

129 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

81 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting·Listed May 2024

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

88 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

for Follicular Lymphoma (FL)

32 locations incl. Fresno

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT06191744·Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

for Colon Adenocarcinoma

31 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06997497·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

for B-Cell Non-Hodgkins Lymphoma

33 locations incl. Anchorage

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06806033·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for Triple Negative Breast Neoplasms

37 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06841354·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

60 locations incl. Gilbert

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

42 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

for Leukemia, Myeloid, Acute

51 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06852222·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

for Glioma

42 locations incl. Birmingham

Sponsor: Nuvation Bio Inc.

Sex: All·Age: 18+

Code: NCT05303519·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

for Cervical Cancer

92 locations incl. Phoenix

Sponsor: Pfizer

Sex: Female·Age: 18+

Code: NCT06952660·Phase 4·Recruiting·Listed May 2025

Apply to this trial

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

for Advanced Melanoma

25 locations incl. Phoenix

Sponsor: Immunocore Ltd

Sex: All·Age: 18+

Code: NCT05549297·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

for Advanced Gastrointestinal Stromal Tumors

8 locations incl. Washington D.C.

Sponsor: Cogent Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT05208047·Phase 3·Recruiting·Listed Jan 2022

Apply to this trial

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

for Small Cell Lung Cancer Extensive Stage

12 locations incl. Santa Rosa

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07227597·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

for Metastatic Melanoma

18 locations incl. Birmingham

Sponsor: Iovance Biotherapeutics, Inc.

Sex: All·Age: 18 - 70

Code: NCT05727904·Phase 3·Recruiting·Listed Feb 2023

Apply to this trial

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

18 locations incl. La Jolla

Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Sex: All·Age: 18+

Code: NCT06667908·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

for Unresectable Melanoma

10 locations incl. Los Angeles

Sponsor: Iovance Biotherapeutics, Inc.

Sex: All·Age: 18 - 70

Code: NCT05361174·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

for Colorectal Cancer

9 locations incl. New Haven

Sponsor: Criterium, Inc.

Sex: All·Age: 18+

Code: NCT06992258·Phase 2·Recruiting·Listed May 2025

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1105 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting·Listed May 2023

Apply to this trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

for Stage III Colon Cancer

922 locations incl. Fairhope

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021

Apply to this trial

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for Locally Advanced Cervical Adenocarcinoma

289 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07061977·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

776 locations incl. Fairhope

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

for B Acute Lymphoblastic Leukemia

156 locations incl. Antioch

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18 - 39

Code: NCT03150693·Phase 3·Recruiting·Listed May 2017

Apply to this trial

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

for Bladder Adenocarcinoma

224 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03866382·Phase 2·Recruiting·Listed Mar 2019

Apply to this trial

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

for Resectable Lung Non-Small Cell Carcinoma

308 locations incl. Fairbanks

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06632327·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

for Locally Advanced Lung Non-Small Cell Carcinoma

446 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05624996·Phase 3·Recruiting·Listed Nov 2022

Apply to this trial

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

for Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma

221 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT01810913·Phase 2, Phase 3·Recruiting·Listed Mar 2013

Apply to this trial

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

for Stage I Breast Cancer

707 locations incl. Mobile

Sponsor: NRG Oncology

Sex: All·Age: 50 - 70

Code: NCT04852887·Phase 3·Recruiting·Listed Apr 2021

Apply to this trial

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for Fallopian Tube Endometrioid Adenocarcinoma

645 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06580314·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

Registry Study for Radiation Therapy Outcomes

for Neoplasms

29 locations incl. Scottsdale

Sponsor: Proton Collaborative Group

Sex: All·Age: All ages

Code: NCT01255748·Recruiting·Listed Dec 2010

Apply to this trial

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

for Acral Lentiginous Melanoma

303 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04511013·Phase 2·Recruiting·Listed Aug 2020

Apply to this trial

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

for Metastatic Clear Cell Renal Cell Carcinoma

340 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04510597·Phase 3·Recruiting·Listed Aug 2020

Apply to this trial

More research sites in Orlando

AdventHealth Orlando (60 trials)
Arnold Palmer Hospital for Children (37 trials)
Nemours Children's Hospital (37 trials)
Orlando Health (31 trials)
University of Central Florida (31 trials)
AdventHealth (28 trials)
Advent Health (17 trials)
Orlando Clinical Research Center (17 trials)
Charter Research (11 trials)
Advent Health Orlando (10 trials)

Explore more

Paid clinical trials in Orlando, FL · Florida clinical trials